1-5 of 5
Mathieu Blery
Close
Sort by
Journal Articles

Lirilumab Enhances Anti-Tumor Efficacy of Elotuzumab

Caroline Sola, PhD, Mathieu Blery, PhD, Cécile Bonnafous, PhD, Elodie Bonnet, Nicolas Fuseri, Robert F Graziano, PhD, Yannis Morel, PhD, Pascale André, PhD
Journal: Blood
Blood (2014) 124 (21): 4711.
https://doi.org/10.1182/blood.V124.21.4711.4711
Published: 2014
Journal Articles

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

Holbrook E. Kohrt, Ariane Thielens, Aurelien Marabelle, Idit Sagiv-Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuseri, Cécile Bonnafous, Debra Czerwinski, Amanda Rajapaksa, Erin Waller, Sophie Ugolini, Eric Vivier, François Romagné, Ronald Levy, Mathieu Bléry, Pascale André
Journal: Blood
Blood (2014) 123 (5): 678–686.
https://doi.org/10.1182/blood-2013-08-519199
Published: 2014
Includes: Supplemental data
Journal Articles

Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies

Holbrook E Kohrt, MD, PhD, Ariane Thielens, Aurelien Marabelle, MD, MSc, Idit Sagiv Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuseri, Cécile Bonnafous, Debra K Czerwinski, Amanda Rajapaksa, Erin Waller, Sophie Ugolini, PhD, Eric Vivier, PhD, Francois Romagne, PhD, Ronald Levy, MD, Pascale Andre, PhD, Mathieu Blery, PhD
Journal: Blood
Blood (2013) 122 (21): 4417.
https://doi.org/10.1182/blood.V122.21.4417.4417
Published: 2013
Journal Articles

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Brief Report
Don M. Benson, Jr, Courtney E. Bakan, Shuhong Zhang, Shauna M. Collins, Jing Liang, Shivani Srivastava, Craig C. Hofmeister, Yvonne Efebera, Pascale Andre, Francois Romagne, Mathieu Bléry, Cécile Bonnafous, Jianying Zhang, David Clever, Michael A. Caligiuri, Sherif S. Farag
Journal: Blood
Blood (2011) 118 (24): 6387–6391.
https://doi.org/10.1182/blood-2011-06-360255
Published: 2011
Includes: Supplemental data
Journal Articles

IPH1101, the First Specific γδ T Cell Agonist, Shows Potent Immuno-Biological Efficacy in Low Grade Follicular Lymphoma Patients When Combined with Rituximab: Results From a Phase II Study.

Claire Lucas, Sophie Ingoure, Elodie Soule, Bruna Faria, Fabien Audibert, Mathieu Blery, Lucile Beautier, Francois Romagne, PhD, Sylvie de Micheaux, MD, Helene Sicard, PhD
Journal: Blood
Blood (2009) 114 (22): 583.
https://doi.org/10.1182/blood.V114.22.583.583
Published: 2009